comparemela.com

Robertl Coleman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Niraparib as Second-line Maintenance Demonstrates Real-world OS Benefit in Recurrent Ovarian Cancer

Second-line maintenance therapy with niraparib improved overall survival vs active surveillance in patients with recurrent BRCA wild-type ovarian cancer.

Overview of Advanced Ovarian Cancer

Robert L Coleman, MD, FACOG, FACS, and Bradley J Monk, MD, FACOG, FACS, provide an overview of advanced ovarian cancer and discuss its prevalence and diagnosis process.

Why Illinois immigrant health care plans got so expensive | Crain s Chicago Business

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.